摘要
目的探讨阿立哌唑联合利培酮治疗慢性精神分裂症的临床疗效与安全性。方法将62例慢性精神分裂症患者随机分为3组，A组21例，口服阿立哌唑联合利培酮治疗，B组21例单用利培酮治疗，C组20例单用阿立哌唑治疗，观察12周。采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗12周末，A组显效率、总有效率均显著高于B组和C组（P〈0．05）；3组不良反应均轻微，发生率比较差异无显著性（P〉0．05）。结论阿立哌唑联合利培酮治疗能有效缓解慢性精神分裂症患者的各种精神症状，且不增加不良反应，安全性高，依从性好，显著优于单用阿立哌唑或利培酮治疗。
Objective To explore the efficacy and safety of aripiprazole combined with risperidone in the treatment of chronic schizophrenia. Methods Sixty two patients with Chronic schizophrenia were randomly divided into group A （n=21） taking orally aripiprazole combined with risperidone, B（n=21） did single risperidone and C （n=20） did single aripiprazole for 12 week. Efficacies were assessed with the Positive anti＇Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results At the end of the 12^th week, obvious and total effective rate were significantly higher in group A than 13 and C （P〈0.05） ; adverse reactions of all 3 groups were mild and their incidences had no significant group differences （P〈0.05）. Conclusion Aripiprazole combined with risperidone could effectively relieve various kinds of mental symptoms, doesn＇t increase adverse reactions, and has higher safety and better compliance compared single aripiprazole or risperidone in the treatment of chronic schizophrenia.
出处
《临床心身疾病杂志》
CAS
2013年第5期410-412,共3页
Journal of Clinical Psychosomatic Diseases
